ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 653

Norepinephrine-Induced IL-6 Regulates Fibrosis In Systemic Sclerosis

Sei-ichiro Motegi, Akihito Uehara, Kazuya Yamada, Akihiko Uchiyama, Sachiko Ogino, Yoko Yokoyama, Yuko Takeuchi and Osamu Ishikawa, Department of Dermatology, Gunma University Graduate School of Medicine, Gunma, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: IL-6, Scleredema and fibroblasts

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Raynaud phenomenon is freaquently observed in patients of systemic sclerosis (SSc) and characterized by episodic vasospasm and ischemia of extremities in response to cold or emotional stress. It has been recogized that cold- or stress-induced norepinephrine (NE) stimulates adrenoreceptor (AR) on pericytes or vascular smooth muscle cells, resulting in vasoconstriction. However, the roles of NE in fibrosis of SSc are not well understood. The aim of this study was to elucidate the role of NE in fibrosis in SSc.

Methods: Protein and mRNA levels of IL-6 and AR expression in normal and SSc fibroblasts treated with or without NE or ARα/β antagonists were measured by ELISA and real-time PCR. The effect of ARβ blocker and ERK inhibitor on NE-induced IL-6 production was analyzed by real-time PCR. The amount of phosphorylation of ERK and total ERK in normal and SSc fibroblasts were measured by Western blot analysis. Proliferation of fibroblasts was determined using the MTS assay.

Results: The serum levels of IL-6 was elevated in patients with early SSc, and correlated with the extent of skin fibrosis. Protein and mRNA levels of IL-6 expression in normal and SSc fibroblasts was increased by NE stimulation in a dose-dependent manner. In addition, NE-induced IL-6 production in SSc fibroblasts was significantly higher than that in normal fibroblasts. The production of IL-6 in fibroblasts was induced by ARβ antagonist, isoproterenol, but not by ARα antagonist, oxymetazoline. ARβ blocker, proplanolol, inhibited NE-induced IL-6 production in normal and SSc fibroblasts, suggesting that NE may induce IL-6 production via ARβ on fibroblasts. There was no change in ARβ expression in normal and SSc fibroblasts treated with or without NE. In addition, proplanolol enhanced NE-induced phosphorylation of ERK, and ERK inhibitor, PD98059, enhanced NE-induced IL-6 production in in normal and SSc fibroblasts, suggesting that NE-induced phosphorylation of ERK via ARα may inhibit NE-induced IL-6 production. Next, we assessed the effect of the treatment with NE and endothelin-1 (ET-1), which is supposed to contribute to the pathogenesis of fibrosis in SSc. Combined treatment with NE and ET-1 resulted in an additive increase in production of IL-6 in SSc fibroblasts. Finally, we identified that NE enhanced proliferation of SSc fibroblasts compared with that of normal fibroblasts.

Conclusion: We conclude that NE enhances IL-6 production and proliferation in SSc fibroblasts via ARβ more than those in normal fibroblasts. Our results indicate that avoidance of cold exposure or emotional stress may attribute to the suppression of fibrosis as well as Raynaud phenomenon in SSc.


Disclosure:

S. I. Motegi,
None;

A. Uehara,
None;

K. Yamada,
None;

A. Uchiyama,
None;

S. Ogino,
None;

Y. Yokoyama,
None;

Y. Takeuchi,
None;

O. Ishikawa,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/norepinephrine-induced-il-6-regulates-fibrosis-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology